Literature DB >> 17010721

Drug delivery systems in urology--getting "smarter".

Omid C Farokhzad1, Jordan D Dimitrakov, Jeffrey M Karp, Ali Khademhosseini, Michael R Freeman, Robert Langer.   

Abstract

Mesh：

Year:  2006        PMID： 17010721      PMCID： PMC1618825          DOI： 10.1016/j.urology.2006.03.069

Source DB:  PubMed          Journal:  Urology        ISSN： 0090-4295            Impact factor:   2.649


× No keyword cloud information.
  44 in total

1.  Differential degradation rates in vivo and in vitro of biocompatible poly(lactic acid) and poly(glycolic acid) homo- and co-polymers for a polymeric drug-delivery microchip.

Authors:  Amy C R Grayson; Gabriela Voskerician; Aaron Lynn; James M Anderson; Michael J Cima; Robert Langer
Journal:  J Biomater Sci Polym Ed       Date:  2004       Impact factor: 3.517

2.  Intraprostatic chemotherapy: distribution and transport mechanisms.

Authors:  M Guillaume Wientjes; Jenny H Zheng; Leijun Hu; Yuebo Gan; Jessie L-S Au
Journal:  Clin Cancer Res       Date:  2005-06-01       Impact factor: 12.531

3.  Biodegradable stents with elastic memory.

Authors:  Subbu S Venkatraman; Lay Poh Tan; Joe Ferry D Joso; Yin Chiang Freddy Boey; Xintong Wang
Journal:  Biomaterials       Date:  2005-09-21       Impact factor: 12.479

4.  Novel delivery of oligonucleotides using a topical hydrogel tissue sealant in a murine partial nephrectomy model.

Authors:  Sanjay Ramakumar; Hardeep Phull; Todd Purves; Joel Funk; Duan Copeland; Judith B Ulreich; Li-Wen Lai; Yeong-Hau Howard Lien
Journal:  J Urol       Date:  2005-09       Impact factor: 7.450

5.  Microfluidic system for studying the interaction of nanoparticles and microparticles with cells.

Authors:  Omid C Farokhzad; Ali Khademhosseini; Sangyong Jon; Aurelia Hermmann; Jianjun Cheng; Curtis Chin; Alice Kiselyuk; Benjamin Teply; George Eng; Robert Langer
Journal:  Anal Chem       Date:  2005-09-01       Impact factor: 6.986

6.  Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer.

Authors:  Neil H Bander; Matthew I Milowsky; David M Nanus; Lale Kostakoglu; Shankar Vallabhajosula; Stanley J Goldsmith
Journal:  J Clin Oncol       Date:  2005-04-18       Impact factor: 44.544

Review 7.  Cancer nanotechnology: opportunities and challenges.

Authors:  Mauro Ferrari
Journal:  Nat Rev Cancer       Date:  2005-03       Impact factor: 60.716

8.  In vivo delivery of BCNU from a MEMS device to a tumor model.

Authors:  Yawen Li; Hong Linh Ho Duc; Betty Tyler; Tiffany Williams; Malinda Tupper; Robert Langer; Henry Brem; Michael J Cima
Journal:  J Control Release       Date:  2005-08-18       Impact factor: 9.776

9.  Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a Phase II prospective multicenter study.

Authors:  Riccardo Bartoletti; Tommaso Cai; Mauro Gacci; Gianluca Giubilei; Fabrizio Viggiani; Giorgio Santelli; Fabio Repetti; Stefano Nerozzi; Paolo Ghezzi; Michele Sisani
Journal:  Urology       Date:  2005-10       Impact factor: 2.649

10.  An evaluation of the pharmacokinetics and pharmacodynamics of the histrelin implant for the palliative treatment of prostate cancer.

Authors:  Martin K Dineen; David S Tierney; Petr Kuzma; Helen S Pentikis
Journal:  J Clin Pharmacol       Date:  2005-11       Impact factor: 3.126
View more
  6 in total

Review 1.  Advances in intravesical therapy for urinary tract disorders.

Authors:  Pradeep Tyagi; Mahendra Kashyap; Harvey Hensley; Naoki Yoshimura
Journal:  Expert Opin Drug Deliv       Date:  2015-10-19       Impact factor: 6.648

2.  State of the art in intravesical therapy for lower urinary tract symptoms.

Authors:  Jonathan Kaufman; Vikas Tyagi; Michele Anthony; Michael B Chancellor; Pradeep Tyagi
Journal:  Rev Urol       Date:  2010

3.  Selective binding of lectins to normal and neoplastic urothelium in rat and mouse bladder carcinogenesis models.

Authors:  Daša Zupančič; Mateja Erdani Kreft; Rok Romih
Journal:  Protoplasma       Date:  2013-07-05       Impact factor: 3.356

4.  Biodegradable intraprostatic doxorubicin implants.

Authors:  Ronnie Ortiz; Jessie L-S Au; Ze Lu; Yuebo Gan; M Guillaume Wientjes
Journal:  AAPS J       Date:  2007-06-29       Impact factor: 4.009

5.  Positively charged cyclodextrins as effective molecular transporters of active phosphorylated forms of gemcitabine into cancer cells.

Authors:  Violeta Rodriguez-Ruiz; Andrey Maksimenko; Giuseppina Salzano; Maria Lampropoulou; Yannis G Lazarou; Valentina Agostoni; Patrick Couvreur; Ruxandra Gref; Konstantina Yannakopoulou
Journal:  Sci Rep       Date:  2017-08-21       Impact factor: 4.379

6.  Safety and efficacy of Intraurethral Mitomycin C Hydrogel for prevention of post-traumatic anterior urethral stricture recurrence after internal urethrotomy.

Authors:  Mahmoudreza Moradi; Katayoun Derakhshandeh; Babak Karimian; Mahtab Fasihi
Journal:  J Inj Violence Res       Date:  2016-04-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.